There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aethlon Medical Inc (NASDAQ:AEMD) and Loxo Oncology (NASDAQ:LOXO) with bullish sentiments.
Aethlon Medical Inc (AEMD)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aethlon Medical Inc today and set a price target of $3. The company’s shares opened today at $1.21, close to its 52-week low of $0.79.
Selvaraju said:
“Our price target is derived from a discounted cash flow-based asset value of $70M for the Hemopurifier, using a 15% discount rate and 0% terminal growth rate, with 40% probability of success. Investment risks include: (1) failure of the Hemopurifier to secure regulatory approval; (2) failure of the Hemopurifier to achieve commercial success due to penetration rate and/or competition; and (3) dilution risk. Aethlon Medical, Inc.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -2.1% and a 36.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Aethlon Medical Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
Loxo Oncology (LOXO)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Loxo Oncology. The company’s shares opened today at $162.08.
Prasad observed:
“We anticipate updated clinical data from LOXO-292 in the second half to bolster the company’s pole position with additional durability data on the patients presented at ASCO.”
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 15.0% and a 55.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
Currently, the analyst consensus on Loxo Oncology is a Strong Buy with an average price target of $216.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
